Stifel raises Johnson & Johnson stock price target on strong earnings

Johnson & Johnson reported Q1 sales of $24.06 billion, topping the $23.6 billion consensus, with adjusted EPS of $2.70 versus $2.68 expected. Several brokers raised targets, including Stifel to $250 from $220, while the company highlighted 5.3% organic sales growth, a 920 bps Stelara biosimilar headwind, and heavy investment costs that should continue into the first half of 2026. Management reiterated double-digit growth by decade-end and outlined 2026 launches for Ottava and THERMOCOOL, supporting a constructive outlook despite near-term pressure.

Analysis

The market is treating this as a clean de-risking event, but the more important signal is that management is effectively buying time with balance-sheet-supported reinvestment. That usually helps multiple expansion in the near term, yet it also raises the bar for visible commercial wins in 12-18 months; if the new launch cadence slips, the stock can re-rate lower even before any fundamental miss shows up in reported numbers.

The second-order winner is the innovation pipeline around robotics and electrophysiology: if these launches execute, they can shift investor focus from patent cliff/biosimilar drag to a higher-duration platform story. The loser is capital intensity discipline—continued heavy spend into 1H26 will pressure near-term incremental margins and could constrain buyback flexibility, which matters because the stock is already close to a technical high and no longer offers much valuation cushion for execution slippage.

Consensus appears to be underweighting the asymmetry between near-term earnings quality and longer-dated optionality. The current setup supports the share price as long as each quarter confirms accelerating mix and launch readiness; however, any sign that the innovation spend is becoming a perpetual tax rather than a bridge to growth would likely compress the multiple quickly. In other words, the stock is less about this quarter’s beat and more about whether management can prove that the next two years are an inflection, not just a maintenance phase.

Key Decisions for Investors

• Stay long JNJ into the next 1-2 quarters, but prefer a covered-call structure or partial trim into strength near prior highs; upside exists, but the payoff is increasingly dependent on execution rather than multiple re-rating.
• Add to JNJ only on post-earnings or launch-related pullbacks over the next 3-6 months; use those dips to buy the thesis that 2026 launch milestones can re-accelerate growth, with downside limited if the balance sheet stays intact.
• Pair trade: long JNJ / short a basket of slower-growing large-cap healthcare names with weaker pipeline visibility over the next 6-12 months; the relative outperformance case is strongest if launch updates continue to validate the reinvestment cycle.
• If holding a short-term bullish view, consider Jan/Apr 2026 call spreads on JNJ rather than outright calls; this targets the launch-catalyst window while capping premium bleed if the market stays in 'prove it' mode.
• Set a hard risk trigger for any sign of margin deterioration without corresponding pipeline milestones over the next 2 reporting cycles; if that happens, reduce exposure because the market will likely start pricing the spend as permanent rather than transitional.